Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster ...

Eli Lilly and Co. and Purdue Strategic Ventures ... Cloud Lab to test formulations to develop injectables, tablets and capsules and topical formulations. The funding round was led by Burlingame ...

extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has cleared the dual inhibitor (JAK3 and TEC), given as a once-daily oral capsule, to treat people aged ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

A Houston-based compounding pharmacy has fired back against a lawsuit filed by the pharmaceutical giant that makes Mounjaro ...

Eli Lilly & Co. and health tech company Kalderos Inc. are seeking to revive lawsuits in the DC Circuit after a federal judge ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...